35,006 Shares of The Cooper Companies, Inc. $COO Purchased by Rakuten Investment Management Inc.

Rakuten Investment Management Inc. bought a new position in The Cooper Companies, Inc. (NASDAQ:COO) in the third quarter, Holdings Channel.com reports. The institutional investor bought 35,006 shares of the medical device company’s stock, valued at approximately $1,982,000.

Several other hedge funds have also modified their holdings of COO. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Cooper Companies during the 3rd quarter worth approximately $3,096,000. ProShare Advisors LLC boosted its stake in Cooper Companies by 2.2% in the third quarter. ProShare Advisors LLC now owns 32,067 shares of the medical device company’s stock valued at $1,813,000 after acquiring an additional 692 shares in the last quarter. Vise Technologies Inc. boosted its stake in Cooper Companies by 23.5% in the third quarter. Vise Technologies Inc. now owns 6,093 shares of the medical device company’s stock valued at $344,000 after acquiring an additional 1,158 shares in the last quarter. International Assets Investment Management LLC boosted its stake in Cooper Companies by 506.0% in the third quarter. International Assets Investment Management LLC now owns 23,166 shares of the medical device company’s stock valued at $1,310,000 after acquiring an additional 19,343 shares in the last quarter. Finally, Generali Asset Management SPA SGR grew its holdings in Cooper Companies by 41.2% in the third quarter. Generali Asset Management SPA SGR now owns 22,621 shares of the medical device company’s stock worth $1,279,000 after purchasing an additional 6,600 shares during the last quarter. 24.39% of the stock is owned by hedge funds and other institutional investors.

Cooper Companies Stock Performance

Shares of Cooper Companies stock opened at $62.36 on Friday. The firm has a market capitalization of $11.86 billion, a P/E ratio of 21.28, a PEG ratio of 2.45 and a beta of 0.83. The company has a quick ratio of 0.73, a current ratio of 1.22 and a debt-to-equity ratio of 0.23. The company has a 50 day moving average price of $59.20 and a 200 day moving average price of $68.61. The Cooper Companies, Inc. has a 52 week low of $51.01 and a 52 week high of $89.83.

Cooper Companies (NASDAQ:COO) last released its earnings results on Wednesday, September 9th. The medical device company reported $1.15 EPS for the quarter, topping analysts’ consensus estimates of $1.12 by $0.03. The company had revenue of $1.07 billion during the quarter, compared to analysts’ expectations of $1.10 billion. Cooper Companies had a net margin of 13.46% and a return on equity of 10.90%. Cooper Companies’s revenue for the quarter was up .5% on a year-over-year basis. During the same period last year, the business earned $0.49 EPS. Cooper Companies has set its Q4 2026 guidance at 1.050-1.090 EPS and its FY 2026 guidance at 4.510-4.550 EPS. Sell-side analysts expect that The Cooper Companies, Inc. will post 4.53 EPS for the current year.

Cooper Companies announced that its board has authorized a stock buyback plan on Wednesday, September 9th that permits the company to buy back $3 billion in outstanding shares. This buyback authorization permits the medical device company to buy up to 22.7% of its stock through open market purchases. Stock buyback plans are generally a sign that the company’s management believes its shares are undervalued.

Analyst Ratings Changes

A number of brokerages have recently issued reports on COO. UBS Group reduced their price target on Cooper Companies from $75.00 to $66.00 and set a “neutral” rating on the stock in a research report on Thursday, September 10th. Robert W. Baird set a $61.00 price objective on Cooper Companies and gave the company a “neutral” rating in a report on Thursday, September 10th. Zacks Research cut Cooper Companies from a “hold” rating to a “strong sell” rating in a research report on Friday, September 11th. JPMorgan Chase & Co. dropped their target price on Cooper Companies from $71.00 to $58.00 and set a “neutral” rating on the stock in a research note on Thursday, September 10th. Finally, Stifel Nicolaus set a $70.00 target price on Cooper Companies and gave the stock a “buy” rating in a research note on Thursday, September 10th. Four equities research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and three have assigned a Sell rating to the company’s stock. According to MarketBeat, Cooper Companies currently has an average rating of “Hold” and an average target price of $68.60.

Insiders Place Their Bets

In related news, Director Lawrence Kurzius acquired 10,000 shares of the company’s stock in a transaction dated Monday, September 14th. The shares were purchased at an average cost of $53.91 per share, with a total value of $539,100.00. Following the completion of the acquisition, the director directly owned 21,099 shares of the company’s stock, valued at $1,137,447.09. This represents a 90.10% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Paul A. Keel bought 4,701 shares of the business’s stock in a transaction that occurred on Friday, September 11th. The stock was purchased at an average cost of $53.18 per share, for a total transaction of $249,999.18. Following the completion of the transaction, the director owned 4,701 shares in the company, valued at $249,999.18. This trade represents a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last quarter, insiders purchased 34,701 shares of company stock valued at $1,880,039. Insiders own 2.08% of the company’s stock.

About Cooper Companies

CooperCompanies is a global medical device company focused on vision care and women’s health. It serves customers in markets around the world through two primary businesses: CooperVision and CooperSurgical.

CooperVision develops and sells contact lenses, including products for daily wear, astigmatism, presbyopia and myopia management. Its offerings include lenses made from silicone hydrogel and other materials, as well as specialty lens options.

CooperSurgical provides products and services for women’s health and fertility care.